Investigational drug · Phase 2
ABD-3001
Also called: DIMATE
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 20, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "ABD-3001"
First trial start
2022
Nov 8, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABD-3001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Acute Myeloid Leukemia, Adult
- Myelodysplastic Syndromes
Approved drugs for the same conditions: Acute myeloid leukemia · Myelodysplastic syndromes · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "ABD-3001" as an intervention, largest first.
Advanced BioDesignIndustry
NCT05601726 · 36 participants (planned) · Start Nov 8, 2022 · Primary completion Jun 2026
Drug: ABD-3001; ABD-3001 · For: Acute Myeloid Leukemia, Adult; Myelodysplastic Syndromes
Sites: Marseille, France; Paris, France; Pierre-Bénite, France
Newest research
PubMed records naming it or its code names, newest first.
- ALDH1 inhibition by DIMATE maintains immune responses and promotes immunogenic remodeling in AML.
Baier C, Colle J, Labiad Y, et al. · Front Immunol 2026
- Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia.
Leonetti F, Kosanovic S, Rebollidos-Rios R, et al. · Hemasphere 2025
- Fluorescent substrates enable specific detection and structure-function insights into human aldehyde dehydrogenase isoforms.
Pequerul R, Covaleda D, Sánchez-Vaca AS, et al. · Chem Biol Interact 2025
- Expression of Aldehyde Dehydrogenase 1A1 in Relapse-Associated Cells in Acute Myeloid Leukemia.
Costello R, Dancik GM, Dubiau A, et al. · Cells 2025
- Reactive oxygen species and aldehyde dehydrogenase 1A as prognosis and theragnostic biomarker in acute myeloid leukaemia patients.
Venton G, Colle J, Tichadou A, et al. · J Cell Mol Med 2024
Also in development for Acute Myeloid Leukemia, Adult
- ClifutinibHEC73543Phase 32 trials
Sunshine Lake Pharma Co., Ltd. · Leukemia, Acute Myeloid (AML), Acute Myeloid Leukemia, Adult
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.